---
schema_version: "secwatch.filing_event.v1"
accession: "0001567892-24-000007"
form_type: "8-K"
ticker: null
cik: "0001567892"
company_name: "Keenova Therapeutics plc"
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:51:20.961540+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mallinckrodt FY2023 net sales $1.87B, EBITDA $572M; guides FY2024 EBITDA $520-560M

## Summary
- FY2023 net sales $1.866B, down 2.5% YoY; Q4 net sales $469.3M (-4.1%).
- FY2023 Adjusted EBITDA $571.9M, above guidance range; Q4 EBITDA $123.8M vs $175.5M.
- Specialty Brands Q4 net sales $270.7M (-15.6%); impacted by Amitiza generic competition.
- Specialty Generics Q4 net sales $198.6M (+17.8%); strong finished-dosage demand.
- 2024 guidance: net sales $1.80-1.90B, Adj. EBITDA $520-560M; FDA approved SelfJect injector.

## SEC filing metadata
- accession: 0001567892-24-000007
- form_type: 8-K
- cik: 0001567892
- company_name: Keenova Therapeutics plc
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567892/000156789224000007/0001567892-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567892/000156789224000007/mnk-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567892-24-000007
- JSON: https://secwatch.observer/filing/0001567892-24-000007.json
- Plain text: https://secwatch.observer/filing/0001567892-24-000007.txt

## Key facts
- Earnings Releases
  Keenova Therapeutics plc updated its the fourth quarter and fiscal year ended December 29, 2023 guidance (raised).
  - Period: the fourth quarter and fiscal year ended December 29, 2023
  - Guidance: raised
  - Result: reported results
  source text: On March 26, 2024, Mallinckrodt plc provided its financial results for the three months and year ended December 29, 2023 as set forth in the attached Exhibit 99.1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567892/000156789224000007/0001567892-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.